Executive SummaryRoutine Blood Screening
Executive Summary • Laboratory Screening

Laboratory-Based Tests and Scores for Screening and Risk Stratification

Comparison of cutoffs, clinical strengths, and diagnostic limitations across routine liver enzymes, platelet count, and the FIB-4 index.

What This Means for Patients

Chances are you already have the raw ingredients for these three checks sitting in your annual lab work. Liver enzymes and platelets by themselves can miss silent liver scarring, which is why plugging age, AST, ALT, and platelets together into the FIB-4 formula is such an effective first screen.

Test Cutoffs Strengths Limitations
Liver enzymes Elevated liver enzymes can indicate liver damage, tissue injury, and/or liver disease1
  • Liver enzymes (ie, ALT, AST, ALP, and GGT) have multiple uses, including screening, diagnosis, and monitoring of patients with a variety of liver diseases2
  • Included in routine laboratory tests2
  • Liver enzymes can be tested individually or as part of a panel2,3
  • Normal levels do not necessarily rule out MASH4
  • Reference range differences affect interpretation5
Platelet count Low: <150,000 platelets/µL6,7

Normal: 150,000–400,000 platelets/µL6,7
  • Platelet count using automated hematology analyzers can be used as a quick and efficient screening biomarker for various conditions in clinical practice8
  • Combining platelet count with other parameters in scoring systems improves diagnostic accuracy in assessing the likelihood of liver fibrosis in the context of MASH7
  • Nonspecific: Low platelet levels can result from multiple causes such as HIV infection or myelodysplastic syndromes9
FIB-4 Low risk of ≥F3: <1.310
Medium risk of ≥F3: 1.3–2.6710
High risk of ≥F3: >2.6710
  • FIB-4 is strongly recommended by current guidelines as a risk stratification tool in primary care to identify patients suitable for ongoing monitoring versus those needing specialist referral7,10-12
  • Reduced specificity in older patients and patients <35 years; secondary assessment recommended in patients <35 years old with higher metabolic risk or elevated liver enzymes10